Start-up to study peptides that modulate gene expression
Drug Discovery World
AUGUST 31, 2023
HBCI was established as a subsidiary of HBC earlier this year, with a focus on the discovery and development of peptides that normalise tumour micro-environments, resulting in the improved performance of immunotherapies and chemotherapies. Other potential cancer indications with ongoing in vitro work include breast and ovarian cancer.
Let's personalize your content